It is not often that high-quality blue chip shares trade at discounted valuations. These are typically businesses with strong competitive advantages, global earnings, and long track records of performance.
But from time to time, even the best companies fall out of favour.
Right now, a handful of ASX blue chips appear to be in that position. Here are three that could be worth a closer look.
CSL Ltd (ASX: CSL)
CSL is widely regarded as one of Australia's highest-quality companies, but the biotech giant's shares have come under pressure in recent times.
This has been driven by earnings misses, margin pressures, a tough operating environment, and leadership changes.
However, these are largely transitional issues rather than structural ones.
CSL still operates a global leader in plasma therapies and vaccines, with strong demand drivers linked to ageing populations and rising healthcare needs. As plasma collection normalises and efficiencies improve, there is potential for margins to recover.
For long-term investors, this could be one of those rare opportunities to buy a premium healthcare business at a more reasonable price.
Cochlear Ltd (ASX: COH)
Another ASX blue chip that could be looking attractive is Cochlear.
Short-term concerns around softer demand have weighed on sentiment. But this does not change the underlying demand for hearing solutions.
Cochlear benefits from a powerful structural tailwind. Hearing loss is a growing global issue, and access to treatment is still underpenetrated in many regions.
The company also enjoys a strong competitive position, supported by technology leadership and a global distribution network.
For investors willing to look beyond near-term noise, Cochlear's long-term growth story appears firmly intact.
Treasury Wine Estates Ltd (ASX: TWE)
A third ASX blue chip that may be undervalued is Treasury Wine Estates.
The company has faced a number of challenges in recent years, including shifting consumer preferences and disruptions to key export markets. These issues have weighed on its share price and created uncertainty around its outlook.
However, Treasury Wine is in the process of reshaping its portfolio.
The focus is increasingly on premium and luxury brands, where margins are higher and demand tends to be more resilient. This shift is helping the company reduce reliance on lower-margin products and improve the quality of its earnings.
In addition, improving trade dynamics and stabilising conditions in key markets could provide a tailwind over time.
While not without risks, Treasury Wine Estates could offer a compelling turnaround opportunity for patient investors.
The post These ASX blue chips now look too cheap to ignore appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in CSL, Cochlear, and Treasury Wine Estates. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, and Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has recommended CSL and Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026